Eagle Pharmaceuticals (EGRX)Receives Orphan Drug Designation For Lower Volume, Shorter Infusion Time Bendamustine Hydrochloride Product For Chronic Lymphocytic Leukemia And Indolent B-Cell Non-Hodgkin’s Lymphoma
7/8/2014 10:48:22 AM
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) announced today that the United States Food and Drug Administration (“FDA”) has granted orphan drug designation to bendamustine hydrochloride (“HCl”), a ready-to-dilute concentrate solution for injection that will be administered by infusion over 10 minutes after dilution in 50mL of sodium chloride (“saline”) or a saline / dextrose mixture, for the treatment of chronic lymphocytic leukemia (“CLL”) and indolent B-cell non-Hodgkin’s lymphoma (“NHL”).
Help employers find you! Check out all the jobs and post your resume.
comments powered by